Tools for Enabling Process Analytical Technology Applications in Biotechnology - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Tools for Enabling Process Analytical Technology Applications in Biotechnology
The success of process analytical technology (PAT), a recent initiative by FDA, depends to a large extent on efficient control of manufacturing processes to achieve predefined quality of the final product. In this paper, the authors review the various analytical methods that can enable use of PAT.

Pharmaceutical Technology
pp. s16-s22, s28-s31

27. K. Hipkins, Pharm. Tech. Eur. 2, 157–163 (2007).

28. C. Justice et al., Biotechnol. Adv. 29, 391–401 (2011).

29. A. Sharma, and S.G. Schulman, Wiley InterScience 2, 172–176 (1999).

30. S. Marose, C. Lindemann, and T. Scheper, Biotech. Progress 14, 63–74, (1998).

31. P. Ana Teixeira et al., Wiley InterScience 102, 1108–1116 (2008).

32. P. Ana Teixeira, M. Tiago Duarte, M.J.T. Carrondo, and M. Paula Alves, Biotechnol.Bioeng. 102, 1852–1861 (2011).

33. M. Reinecke and T. Scheper, J. Biotechnol. 17, 145–53 (1997).

34. A.S. Rathore, L. Parr, S. Dermawan, K. Lawson, and Y. Lu, Biotechnol. Prog. 26, 448–57 (2010).

35. A.S. Rathore, R. Wood, A. Sharma, and S. Dermawan, Biotechnol. Bioeng. 101, 1366–1374 (2008).

36. A.S. Rathore, A. Sharma, and D. Chilin, BioPharm Int. 19, 48–57 (2006).

37. M. Tina Larson et al., Biotech. and Bioengin. 77, 553–563 (2002).

38. R.L. Fahrner et al., J. Chromatogr. A. 827, 37–43 (1998).

39. J. Barackman, I.Prado, C. Karunatilake, and K. Furuya, J. Chromatogr. A. 16, 57–64 (2004).

40. C. Bittner, G. Wehnert, and T. Scheper, Biotechnol. Bioeng. 60, 24–35 (1998).

41. V. Camisard et al., Biotechnol. Bioeng. 78, 73–80 (2002).

42. J.S. Guez et al., J. Biotechnol. 111, 335–343 (2004).

43. G. Rudolph et al., Biotechnol. Bioeng. 99, 136–145 (2008).

44. N. Wei et al., Biotechnol. Lett. 29, 373–378 (2007).

45. A. Prediger et al., Chem. Engin. & Tech. 34, 837–840 (2011).

46. C. Buschmüller et al., Eur. J. Pharm. Biopharm. 69, 380–387 (2008).


48. M.P. Wagh, Y.H. Sonawane, and O.U. Joshi., Indian J. Pharm. Sci. 71, 235–241 (2009).

49. H. Wu, E.J. Heilweil, A.S, Hussain, and M.A. Khan, J. Pharm. Sci. 97, 970–984 (2008).

50. T. Schmid, Anal. Bioanal. Chem. 384, 1071–1086 (2006).

51. V. Deepak Bageshwar, S. Avinash Pawar, V. Vineeta Khanvilkar, and J. Vilasrao Kadam, Eurasian J. Anal. Chem. 5, 187–203 (2010).

52. T. Schmid et al., Environ. Sci. Technol. 36, 4135–4141 (2002).


54. W. Chew and P. Sharratt, Anal. Methods 2, 1412–1438 (2010).

55. P. Werle, R. Mücke, and F. Slemr, App. Phys. B: Lasers and Optics 57, 131–139 (1993).

56. S. Armenta, S. Garrigues, M. Gauradia, and P. Rondeau, Anal. Chem. Acta. 545, 99–106 (2005).

57. A.S. Rathore, R. Bhambure, and V. Ghare, Bioanal. Chem. 398, 137–154 (2010).

*This article was previously published in the January 2012 issue of LCGC North America.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here